Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2a + adefovir
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This drug is a combination of interferon alfa-2a and adefovir. Interferon alfa-2a is a recombinant cytokine that binds to the interferon alpha/beta receptor, activating intracellular signaling pathways that induce antiviral, antiproliferative, and immunomodulatory effects. Adefovir (commonly abbreviated as ADV) is an oral nucleotide analog reverse transcriptase inhibitor with potent activity against hepatitis B virus (HBV); it inhibits viral DNA polymerase by competing with natural substrates and causing chain termination during viral replication. The combination has been explored for the treatment of chronic hepatitis B infection to enhance antiviral efficacy by combining immune modulation (interferon) with direct inhibition of HBV replication (adefovir).
- Other names
- interferon alfa-2a + ADVinterferon alpha-2a + adefovir
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HBV Pol (Hepatitis B virus polymerase)POLG (Mitochondrial DNA polymerase gamma)POLA1 (DNA polymerase alpha)
Beyond the preview
Go deeper on interferon alfa-2a + adefovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2a + adefovir.